Transcription factor; can act both as activator and as repressor. Binds the 5'-CACCC-3' core sequence. Binds to the promoter region of its own gene and can activate its own transcription. Regulates the expression of key transcription factors during embryonic development. Plays an important role in maintaining embryonic stem cells, and in preventing their differentiation. Required for establishing the barrier function of the skin and for postnatal maturation and maintenance of the ocular surface. Involved in the differentiation of epithelial cells and may also function in skeletal and kidney development. Contributes to the down-regulation of p53/TP53 transcription. Interacts with POU5F1/OCT4 and SOX2. Interacts with MUC1 (via the C-terminal domain). Belongs to the krueppel C2H2-type zinc-finger protein family. 3 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: DNA-binding; Transcription factor; C2H2-type zinc finger protein
Biological Process: fat cell differentiation; inhibition of NF-kappaB transcription factor; mesodermal cell fate determination; negative regulation of caspase activity; negative regulation of cell proliferation; negative regulation of heterotypic cell-cell adhesion; negative regulation of inflammatory response; negative regulation of interleukin-8 biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; positive regulation of cellular protein metabolic process; positive regulation of hemoglobin biosynthetic process; positive regulation of nitric oxide biosynthetic process; positive regulation of protein metabolic process; positive regulation of telomerase activity; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; post-embryonic hemopoiesis; regulation of cell differentiation; somatic stem cell maintenance; stem cell maintenance; transcription from RNA polymerase II promoter
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.